Satralizumab-mwge: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

30 April 2025

  • curprev 18:2218:22, 30 April 2025 Alara E. Dagsali talk contribs 21,434 bytes +21,434 Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=satralizumab-mwge |aOrAn=a |drugClass=interleukin inhibitors |indication=ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. |adverseReactions=The following clinically significant adverse reactions are described elsewhere in the labeling: *Infections *Elevated Liver Enzym..."
Retrieved from "https://www.wikidoc.org/index.php/Satralizumab-mwge"